Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help blood disorder patients when standard care fails

NCT ID NCT07007962

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed first-line treatment. The goal is to see if the drug can raise platelet counts to safer levels. About 60 people will take the drug for up to 28 weeks, with some continuing longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history * Participant received at least one course of first-line therapy and had a history of response while on treatment * Participant has loss of response, relapse, or steroid dependency Key Exclusion Criteria: * Participants with Secondary ITP * Participants with Evans syndrome or history of myelodysplastic syndrome * Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy. * Participants with history of solid organ transplant * Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP * Participant received advanced therapy for ITP or was splenectomized * Pregnancy or nursing The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    36 sites in 9 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Community Cancer Trials of Utah-Investigational Site Number: 8400002

    RECRUITING

    Ogden, Utah, 84405, United States

  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates)

    RECRUITING

    Clovis, California, 93611, United States

  • Investigational Site Number : 0400001

    RECRUITING

    Vienna, 1140, Austria

  • Investigational Site Number : 2030002

    RECRUITING

    Prague, 12800, Czechia

  • Investigational Site Number : 2500001

    RECRUITING

    Dijon, 21079, France

  • Investigational Site Number : 2500002

    RECRUITING

    Pessac, 33604, France

  • Investigational Site Number : 2500004

    RECRUITING

    Toulouse, 31059, France

  • Investigational Site Number : 2760004

    RECRUITING

    Leipzig, 04103, Germany

  • Investigational Site Number : 3480001

    RECRUITING

    Budapest, Hungary

  • Investigational Site Number : 3480002

    RECRUITING

    Kaposvár, 7400, Hungary

  • Investigational Site Number : 3800002

    RECRUITING

    Meldola, Italy

  • Investigational Site Number : 3800003

    RECRUITING

    Vicenza, 36100, Italy

  • Investigational Site Number : 3800004

    RECRUITING

    Milan, 20162, Italy

  • Investigational Site Number : 3800006

    RECRUITING

    Naples, 80131, Italy

  • Investigational Site Number : 3800007

    RECRUITING

    Torino, 10126, Italy

  • Investigational Site Number : 6160002

    RECRUITING

    Gdansk, 80-219, Poland

  • Investigational Site Number : 6160003

    RECRUITING

    Skorzewo, 60-185, Poland

  • Investigational Site Number : 6160004

    RECRUITING

    Słupsk, 76-200, Poland

  • Investigational Site Number : 7240001

    RECRUITING

    Barcelona, 8003, Spain

  • Investigational Site Number : 7240002

    RECRUITING

    Burgos, 9006, Spain

  • Investigational Site Number : 7240003

    RECRUITING

    San Cristóbal de La Laguna, Spain

  • Investigational Site Number : 7240004

    RECRUITING

    Seville, 41013, Spain

  • Investigational Site Number : 7240005

    RECRUITING

    Murcia, 30008, Spain

  • Investigational Site Number : 7240007

    RECRUITING

    Madrid, 28007, Spain

  • Investigational Site Number : 7240008

    RECRUITING

    Madrid, 28046, Spain

  • Investigational Site Number: 2500003

    RECRUITING

    Créteil, 94000, France

  • Mass General Brigham Cancer Institute

    RECRUITING

    Danvers, Massachusetts, 01923, United States

  • Massachusetts General Hospital Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic_Investigational Site Number: 8400009

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Montefiore Medical Center-Investigational Site Number: 8400012

    RECRUITING

    The Bronx, New York, 10467, United States

  • New York Oncology Hematology-Investigational Site Number: 8400010

    RECRUITING

    Albany, New York, 12208, United States

  • Oregon Health and Sciences University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Southern California (USC)

    RECRUITING

    Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.